New dosing options for xywav could help fight daytime sleepiness
NCT ID NCT07625280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tests whether expanded dosing regimens of Xywav can safely reduce excessive daytime sleepiness in adults with narcolepsy or idiopathic hypersomnia. About 108 participants will receive either Xywav or a placebo in a randomized withdrawal design. The main goal is to see if sleepiness scores improve on the Epworth Sleepiness Scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Xywav (calcium, magnesium, potassium, and sodium oxybates solution)
What this could lead to
If successful, this could offer more flexible dosing options for Xywav to better control daytime sleepiness in people with narcolepsy or idiopathic hypersomnia.
What could go wrong
This is a relatively small Phase 3 trial (108 participants) and uses a randomized withdrawal design, so results may not apply to everyone. Xywav can cause side effects like dizziness, nausea, and sleepwalking.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Intrepid Research
Cincinnati, Ohio, 45245, United States